Thermo Fisher Scientific Inc (TMO) Shares Sold by Nomura Holdings Inc.

Nomura Holdings Inc. reduced its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 90.7% during the first quarter, Holdings Channel reports. The fund owned 2,114 shares of the medical research company’s stock after selling 20,545 shares during the period. Nomura Holdings Inc.’s holdings in Thermo Fisher Scientific were worth $325,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the company. Independent Portfolio Consultants Inc. increased its stake in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock worth $112,000 after buying an additional 2 shares during the last quarter. Sharkey Howes & Javer increased its stake in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares during the last quarter. Penserra Capital Management LLC increased its stake in Thermo Fisher Scientific by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,150 shares of the medical research company’s stock worth $176,000 after buying an additional 100 shares during the last quarter. South Texas Money Management Ltd. bought a new stake in Thermo Fisher Scientific during the first quarter worth about $202,000. Finally, Fairfax Financial Holdings Ltd Can bought a new stake in Thermo Fisher Scientific during the first quarter worth about $206,000. Institutional investors own 87.15% of the company’s stock.

Thermo Fisher Scientific Inc (NYSE:TMO) traded up 0.82% on Friday, reaching $173.15. 455,456 shares of the company were exchanged. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $182.87. The stock has a 50 day moving average of $176.85 and a 200 day moving average of $165.24. The firm has a market capitalization of $67.55 billion, a PE ratio of 30.17 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.03 earnings per share. Equities analysts anticipate that Thermo Fisher Scientific Inc will post $9.24 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.

ILLEGAL ACTIVITY WARNING: “Thermo Fisher Scientific Inc (TMO) Shares Sold by Nomura Holdings Inc.” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/08/11/thermo-fisher-scientific-inc-tmo-shares-sold-by-nomura-holdings-inc.html.

TMO has been the subject of a number of research analyst reports. Deutsche Bank AG increased their target price on shares of Thermo Fisher Scientific from $163.00 to $188.00 and gave the stock a “buy” rating in a research report on Friday, April 28th. BTIG Research increased their target price on shares of Thermo Fisher Scientific from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Friday, April 28th. Barclays PLC set a $175.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Wednesday, April 26th. Leerink Swann set a $187.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Thursday, April 27th. Finally, Bank of America Corporation increased their target price on shares of Thermo Fisher Scientific from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, May 9th. One research analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $188.56.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the sale, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $176.26, for a total transaction of $440,650.00. Following the sale, the chief financial officer now directly owns 37,790 shares in the company, valued at $6,660,865.40. The disclosure for this sale can be found here. In the last three months, insiders sold 27,188 shares of company stock worth $4,702,223. 0.49% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit